专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

US20090208575A1 Pharmaceutical Composition Of Acid Labile Substances 审中-公开
标题翻译：酸不稳定物质的药物组成
公开(公告)号：US20090208575A1
公开(公告)日：2009-08-20
申请号：US11794748
申请日：2006-01-03
申请人： Jyothi Lakshmi Gunupati , Suryakumar Jayanthi , Himadri Sen
发明人： Jyothi Lakshmi Gunupati , Suryakumar Jayanthi , Himadri Sen
IPC分类号： A61K9/30 , A61K31/4439
CPC分类号： A61K31/133 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K9/2846 , A61K9/2866 , A61K9/2886 , A61K31/4439 , A61K2300/00
摘要： A pharmaceutical composition for oral use comprising a) a core comprising an effective amount of benzimidazole and an organic stabilizing agent which is present in an amount effective to stabilize the composition, b) an intermediate layer comprising of a water insoluble polymer and an organic stabilizer, and c) an outer enteric coating layer. The organic stabilizing agent is present in the core from about 1% to about 10% by weight of the core and in the intermediate layer from about 5% to about 35% by weight of intermediate layer.
摘要翻译：一种用于口服使用的药物组合物，其包含a）包含有效量的苯并咪唑和有效稳定组合物的有机稳定剂的核心，b）包含水不溶性聚合物和有机稳定剂的中间层，和c）外肠衣层。有机稳定剂在核心中以核心的约1重量％至约10重量％存在，中间层中存在约5重量％至约35重量％的中间层。

32. 发明申请

US20080102134A1 CONTROLLED RELEASE COLOR STABLE PHARMACEUTICAL DOSAGE FORM OF HMG-COA REDUCTASE INHIBITORS, FREE OF ALKALIZING OR BUFFERING AGENTS 审中-公开
标题翻译： HMG-COA还原抑制剂的控制释放颜色稳定的药物剂型，不含碱化剂或缓冲剂
公开(公告)号：US20080102134A1
公开(公告)日：2008-05-01
申请号：US11870744
申请日：2007-10-11
申请人： Dhanashree Mistry , Dhananjay Panigrahi , T. Kumar , Himadri Sen
发明人： Dhanashree Mistry , Dhananjay Panigrahi , T. Kumar , Himadri Sen
IPC分类号： A61K9/16 , A61K31/404 , A61K47/38
CPC分类号： A61K31/405 , A61K9/1652 , A61K9/2077 , A61K9/2866
摘要： A color stable controlled release pharmaceutical dosage form comprising HMG CoA reductase inhibitor, rate controlling polymers and one or more pharmaceutical excipients wherein the granules are independent of particle size the pharmaceutical dosage form is free of alkalizing/buffering agents. A color stable controlled release pharmaceutical dosage form comprising Fluvastatin Sodium, hydroxypropyl methylcellulose polymer and hydroxypropyl cellulose, wherein the granules are independent of particle size.
摘要翻译：包含HMG CoA还原酶抑制剂，速率控制聚合物和一种或多种药物赋形剂的颜色稳定的控释药物剂型，其中所述颗粒与颗粒大小无关，药物剂型不含碱化/缓冲剂。包含氟伐他汀钠，羟丙基甲基纤维素聚合物和羟丙基纤维素的颜色稳定的控释药物剂型，其中颗粒独立于粒度。

33. 发明申请

US20060149056A1 Stable bioavailable crystalline form of cefdinir and a process for the preparation thereof 审中-公开
标题翻译：头孢地尼的稳定的生物可利用结晶形式及其制备方法
公开(公告)号：US20060149056A1
公开(公告)日：2006-07-06
申请号：US11365915
申请日：2006-03-02
申请人： Girij Singh , Himadri Sen , Dhananjai Srivastava , Himanshu Godbole , Gurvinder Singh , Pravin Mahajan , Umesh Rananaware , Sagar Nehate , Sanjay Wagh
发明人： Girij Singh , Himadri Sen , Dhananjai Srivastava , Himanshu Godbole , Gurvinder Singh , Pravin Mahajan , Umesh Rananaware , Sagar Nehate , Sanjay Wagh
IPC分类号： C07D501/14
CPC分类号： C07D501/00
摘要： The present invention relates to a stable and bioavailable crystalline form of a third generation cephalosporin antibiotic, cefdinir and a process for the preparation thereof. The present invention also relates to a pharmaceutical composition containing the novel crystalline cefdinir, useful in the treatment of maladies such as bacterial infections.
摘要翻译：本发明涉及第三代头孢菌素抗生素，头孢地尼的稳定和生物可利用的结晶形式及其制备方法。本发明还涉及含有新型结晶头孢地尼的药物组合物，其可用于治疗诸如细菌感染的疾病。

34. 发明申请

US20050084455A1 Inhalable biodegradable microparticles for target-specific drug delivery in tuberculosis and a process thereof 审中-公开
标题翻译：用于结核分枝杆菌靶向特异性药物递送的可吸入的可生物降解微粒及其制备方法
公开(公告)号：US20050084455A1
公开(公告)日：2005-04-21
申请号：US10685567
申请日：2003-10-16
申请人： Himadri Sen , Suryakumar Jayanthi , Rakesh Sinha , Rolee Sharma , Pawan Muttil
发明人： Himadri Sen , Suryakumar Jayanthi , Rakesh Sinha , Rolee Sharma , Pawan Muttil
IPC分类号： A61K9/00 , A61K9/16 , A61K31/00 , A61K31/445 , A61K31/455 , A61L9/04 , A61K9/14 , A61K31/496
CPC分类号： A61K9/0075 , A61K9/0053 , A61K9/1647 , A61K31/00 , A61K31/445 , A61K31/455
摘要： The present invention relates to a biodegradable microparticle composition useful for the target specific drug delivery to manage pulmonary tuberculosis, said composition comprising two anti-tuberculosis drugs, and a biodegradable polymer for drug delivery in a ratio of about 1:2 to 2:1, wherein the anti-tubercular drugs are in the ratio of 1:2 to 2:1, also, a process for the preparation of the composition, and lastly, a method of treating pulmonary tuberculosis in a subject, said method comprising administering by inhalation alone or in combination with oral route, pharmaceutically effective amount of the composition to the subject in need thereof, wherein the dosage for inhalation is ranging between 0.5 to 10 mg/kg body weight/day and that for oral route is ranging between 4 to 32 mg/kg body weight/day.
摘要翻译：本发明涉及可用于目标特异性药物递送以管理肺结核的可生物降解的微粒组合物，所述组合物包含两种抗结核药物和用于药物递送的生物可降解聚合物，其比例为约1:2至2:1，其中抗结核药物的比例为1:2至2:1，也是制备组合物的方法，最后是治疗受试者肺结核的方法，所述方法包括单独给药或与口服途径组合的药物有效量的组合物与有需要的受试者组合，其中吸入剂量为0.5至10mg / kg体重/天，口服途径的范围为4至32mg / kg体重/天。

35. 发明授权

US06586005B1 Extended release formulation of etodolac 失效
标题翻译：依托度酸的延长释放制剂
公开(公告)号：US06586005B1
公开(公告)日：2003-07-01
申请号：US09648949
申请日：2000-08-25
申请人： Rajeev S. Raghuvanshi , Ashok Rampal , Himadri Sen
发明人： Rajeev S. Raghuvanshi , Ashok Rampal , Himadri Sen
IPC分类号： A61K922
CPC分类号： A61K31/407 , A61K9/2054
摘要： A sustained release formulation of etodolac for once daily administration is described.
摘要翻译：描述了一次一次给药的依托度酸缓释制剂

36. 发明授权

US06323193B1 Bioavailable oral dosage form of cefuroxime axetil 失效
标题翻译：头孢呋辛酯的生物利用口服剂型
公开(公告)号：US06323193B1
公开(公告)日：2001-11-27
申请号：US09642402
申请日：2000-08-21
申请人： Jitendra Krishan Somani , Indu Bhushan , Himadri Sen
发明人： Jitendra Krishan Somani , Indu Bhushan , Himadri Sen
IPC分类号： A61K31545
CPC分类号： A61K9/2095 , Y10S514/944
摘要： This invention relates to a bioavailable oral dosage form comprising of amorphous cefuroxime axetil containing from 7 to 25% crystalline cefuroxime axetil.
摘要翻译：本发明涉及一种生物可利用的口服剂型，其包含含有7-25％结晶头孢呋辛酯的无定形头孢呋辛酯。

37. 发明授权

US5728401A Effervescent ranitidine formulations 失效
标题翻译：泡腾雷尼替丁配方
公开(公告)号：US5728401A
公开(公告)日：1998-03-17
申请号：US837488
申请日：1997-04-16
申请人： Farhan Ahmed , Chetan Rajsharad , Himadri Sen
发明人： Farhan Ahmed , Chetan Rajsharad , Himadri Sen
IPC分类号： A61K9/46 , A61K31/341
CPC分类号： A61K31/341 , A61K9/0007
摘要： An effervescent pharmaceutical composition for oral use in the treatment of a condition mediated through histamine H.sub.2 receptors contains a therapeutically effective amount of ranitidine or a physiologically acceptable salt thereof, about 25-70% by weight of disodium citrate, and about 20-50% by weight of sodium bicarbonate. Optionally, the effervescent composition may also Include about 0.5-25% by weight of an edible organic acid such as fumaric acid. Preferably, the effervescent composition is in the form of a tablet. Additional excipients for the effervescent composition include about 2-10% by weight of glycine, a flavoring agent, a sweetening agent, a binding agent, and/or a lubricant.
摘要翻译：用于口服用于治疗由组胺H2受体介导的病症的泡腾药物组合物含有治疗有效量的雷尼替丁或其生理上可接受的盐，约25-70重量％柠檬酸二钠，约20-50％重量的碳酸氢钠。任选地，泡腾组合物还可以包括约0.5-25重量％的可食用有机酸如富马酸。优选地，泡腾组合物是片剂的形式。用于泡腾组合物的附加赋形剂包括约2-10重量％的甘氨酸，调味剂，甜味剂，粘合剂和/或润滑剂。

38. 发明授权

US5137730A Tablet composition and method for problem pharmaceutical materials using citric acid 失效
标题翻译：酪氨酸组合物和使用柠檬酸的问题药物材料的方法
公开(公告)号：US5137730A
公开(公告)日：1992-08-11
申请号：US705829
申请日：1991-05-28
申请人： Andrew B. Dennis , Peter Timmins , Himadri Sen
发明人： Andrew B. Dennis , Peter Timmins , Himadri Sen
IPC分类号： A61K9/20 , A61K31/135 , A61K31/137 , A61K31/55 , A61K47/12
CPC分类号： A61K9/2013 , A61K9/2077 , Y10S514/96
摘要： In accordance with the present invention an improved tablet composition for drugs or active ingredients prone to poor tabletting properties is disclosed. The improved composition comprises a premixture, consisting essentially of between about 85 and 99.9 percent by weight of the active ingredient and between about 0.1 and 15 percent by weight of citric acid, and one or more other formulation ingredients added to premixture. The present invention also involves the process for making such compositions and products therefrom.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式